Pharmacokinetics and Pharmacodynamics Practice Questions

Q: A patient requires immediate relief from an acute asthma attack. Which route of administration would provide the fastest effect?

Inhalation. ***Inhalation*** - **Inhalation** delivers medication directly to the **airways**, the site of action for asthma, allowing for rapid absorption and immediate local bronchodilation. - This route provides **targeted drug delivery** to bronchial smooth muscle, achieving therapeutic effect within **1-5 minutes** for acute asthma relief. - Bypasses first-pass metabolism and requires **lower doses** due to direct delivery to the target organ. - **First-line treatment** for acute asthma attacks in clinical practice. *Oral* - **Oral administration** involves absorption from the gastrointestinal tract, which is a slower process, with onset typically taking **30-60 minutes**. - Medications taken orally undergo **first-pass metabolism** in the liver, reducing bioavailability and delaying therapeutic effect. - Not suitable for **acute** asthma management due to delayed onset. *Subcutaneous* - **Subcutaneous injections** are absorbed more slowly than intravenous or inhaled routes, with onset in **15-30 minutes**. - The drug must diffuse from subcutaneous tissue into the bloodstream before reaching the lungs. - May be used for severe asthma (e.g., subcutaneous epinephrine) but **not preferred** over inhalation for typical acute attacks. *Intravenous* - While **intravenous administration** provides immediate systemic delivery with rapid onset, it is **not the first choice** for acute asthma. - Reserved for **severe, life-threatening asthma** unresponsive to inhaled therapy. - Requires IV access, medical supervision, and carries higher risk of systemic side effects. - For acute asthma relief, **inhaled bronchodilators act faster at the target site** despite IV having faster systemic absorption.

Q: A patient with a severe infection is given a drug with a half-life of 8 hours. How long will it take for the drug's concentration to decrease to 25% of its original value?

16 hours. ***16 hours (Correct)*** - After one **half-life** (8 hours), the drug concentration will be 50% of the original value. - After two half-lives (8 hours + 8 hours = **16 hours**), the drug concentration will be 25% of the original value (50% of 50%). - This follows the exponential decay formula: remaining concentration = (1/2)^n, where n is the number of half-lives. *8 hours (Incorrect)* - This represents only one half-life, at which point the drug's concentration would be reduced to 50%, not 25%, of its original value. - The question asks for the time to reach 25% concentration, which requires an additional half-life. *24 hours (Incorrect)* - This duration represents three half-lives (8 hours × 3). - After three half-lives, the drug concentration would be 12.5% of its original value (50% → 25% → 12.5%). *32 hours (Incorrect)* - This duration represents four half-lives (8 hours × 4). - After four half-lives, the drug concentration would be 6.25% of its original value (12.5% → 6.25%).

Q: Comparing cisplatin and carboplatin, which factor primarily accounts for the difference in nephrotoxicity between these two chemotherapeutic agents?

Different rates of renal clearance. ***Different rates of renal clearance*** - **Cisplatin** is largely cleared by **glomerular filtration** and **tubular secretion**, leading to higher concentrations in the renal tubules and increased nephrotoxicity. - **Carboplatin** is primarily cleared by **glomerular filtration** without significant tubular secretion, resulting in lower renal exposure and reduced nephrotoxicity. *Variability in DNA adduct formation* - While both drugs form DNA adducts to exert their therapeutic effect, the specific differences in adduct formation do not primarily explain their differential nephrotoxicity. - The mechanism of nephrotoxicity is more related to the drugs' delivery and concentration in renal cells rather than the inherent nature of their DNA-damaging activity. *Difference in protein binding* - Both cisplatin and carboplatin bind to plasma proteins, but this factor alone does not account for the significant difference in their nephrotoxic profiles. - Protein binding can influence drug distribution and elimination, but the **intrinsic renal handling** mechanisms are more critical for specific organ toxicity. *Dose-dependent cellular uptake* - Both drugs exhibit dose-dependent cellular uptake in target cancer cells, which is crucial for efficacy. - However, the **differential nephrotoxicity** is more closely tied to their **pharmacokinetics** within the kidney itself (e.g., clearance rates) rather than just general cellular uptake.

Q: What is the formula for calculating the therapeutic index (TI) of a drug?

LD50/ED50. ***LD50/ED50*** - The **therapeutic index (TI)** is calculated as the ratio of the **lethal dose for 50% of the population (LD50)** to the **effective dose for 50% of the population (ED50)**. - A higher TI indicates a wider margin of safety, meaning a larger dose is required to produce toxic effects compared to the dose producing therapeutic effects. *EC50/IC50* - This ratio compares the **half maximal effective concentration (EC50)** to the **half maximal inhibitory concentration (IC50)**. - While these terms are important in pharmacology for understanding drug potency and inhibition, they do not directly represent the therapeutic index. *IC50/EC50* - This is the inverse of the previous option, comparing IC50 to EC50. - This ratio is not used for calculating the **therapeutic index**; it might be relevant for understanding the balance between a drug's desired effect and its ability to inhibit a specific process. *ED50/LD50* - This formula represents the inverse of the **therapeutic index**. - A low value of this ratio would indicate a safer drug, but the standard calculation for TI uses LD50 in the numerator to reflect the margin of safety.

Q: Which route of administration provides the fastest onset of action for medications?

Intravenous. ***Intravenous*** - **Intravenous (IV)** administration directly introduces the medication into the bloodstream, bypassing **absorption barriers**. - This route ensures **100% bioavailability** and the most rapid distribution to target tissues, leading to the fastest onset of action. *Oral* - Oral medications must undergo **absorption** from the gastrointestinal tract and first-pass metabolism in the **liver** before reaching systemic circulation. - This process significantly **delays** the onset of action compared to IV administration. *Intramuscular* - Intramuscular (IM) injections deliver medication into muscle tissue, which is relatively **vascular**, allowing for faster absorption than oral or subcutaneous routes. - However, absorption is still dependent on **muscle blood flow** and drug properties, making it slower than direct IV administration. *Subcutaneous* - Subcutaneous (SC) injections deliver medication into the **fatty tissue** layer beneath the skin. - Absorption from this site is generally **slower** and more sustained compared to IM or IV due to poorer vascularity.

Q: In a drug exhibiting first-order kinetics, how would an increase in dose affect the time required to reach the steady-state concentration?

It would not change. ***It would not change*** - For drugs following **first-order kinetics**, the time required to reach steady-state concentration is determined solely by the **half-life (t½)** of the drug, which is independent of the dose. - Steady-state is generally achieved after approximately **4 to 5 half-lives**, regardless of the administered dose size, provided the dosing interval remains constant. *It would decrease* - An increase in dose does not shorten the time to reach steady state for a first-order drug, as the **elimination rate** is proportional to the plasma concentration. - The drug still needs to undergo the same number of half-lives to accumulate to a steady level. *It would increase* - Increasing the dose does not prolong the time to reach steady state for a drug exhibiting first-order kinetics. - The **kinetics of elimination** remain proportional to the amount of drug in the body, meaning a larger dose will be eliminated proportionally faster, maintaining the same half-life. *It would double* - The time to reach steady state is a function of the drug's elimination half-life, not the magnitude of the dose. - Doubling the dose will **double the steady-state concentration**, but not the time it takes to achieve that concentration.

Q: Which of the following drugs is not an inhibitor of P-glycoprotein?

Phenobarbitone. ***Phenobarbitone*** - **Phenobarbitone** is primarily known as an **inducer** of various metabolic enzymes, including CYP450 enzymes and **P-glycoprotein itself**. - Unlike the other options, it **increases P-glycoprotein expression** (upregulation) rather than inhibiting its function. - This induction leads to enhanced drug efflux and reduced bioavailability of P-gp substrate drugs, which is the opposite effect of P-gp inhibitors [1]. *Quinidine* - **Quinidine** is a well-known and potent **inhibitor of P-glycoprotein**, often used as a reference compound in studies of P-gp modulation. - It can significantly increase the bioavailability and reduce the elimination of P-gp substrate drugs by blocking the efflux pump. *Verapamil* - **Verapamil** is a potent **calcium channel blocker** and also a significant **inhibitor of P-glycoprotein** [2]. - Its P-gp inhibitory activity contributes to clinical drug interactions by increasing the systemic exposure of co-administered P-gp substrate drugs. *Erythromycin* - **Erythromycin**, a macrolide antibiotic, is a known **inhibitor of P-glycoprotein** [3]. - This inhibition can lead to increased concentrations of co-administered P-gp substrates, contributing to potential drug toxicities.

Q: What is the primary reason for the short half-life of adenosine in the bloodstream?

Rapid uptake by red blood cells and endothelial cells. ***Rapid uptake by red blood cells and endothelial cells*** - **Adenosine** is rapidly transported into cells, particularly **red blood cells** and **vascular endothelial cells**, via specific **nucleoside transporters**. - Once inside these cells, adenosine is quickly metabolized by **adenosine deaminase** into inosine or phosphorylated by **adenosine kinase** into AMP, limiting its systemic half-life to a few seconds. *Uptake in subcutaneous tissue of adenosine* - While some uptake might occur in various tissues, **subcutaneous tissue** is not the primary site responsible for the rapid clearance and extremely short half-life of adenosine in the bloodstream. - The rapid action and metabolism of adenosine primarily occur in the **vascular compartment** and circulating blood cells. *Renal excretion of adenosine* - **Renal excretion** plays a minor role in the elimination of intact adenosine from the bloodstream due to its rapid cellular uptake and metabolism. - The majority of adenosine is metabolized intracellularly before it can be filtered by the kidneys. *Spontaneous hydrolysis of adenosine* - **Spontaneous hydrolysis** is not a significant mechanism contributing to the rapid breakdown and short half-life of adenosine in the human body. - Enzymatic degradation by **adenosine deaminase** is the primary catabolic pathway.

Question 1

A patient requires immediate relief from an acute asthma attack. Which route of administration would provide the fastest effect?

Accepted Answer

Inhalation

Answer

Oral

Answer

Subcutaneous

Answer

Intravenous

Question 2

A patient with a severe infection is given a drug with a half-life of 8 hours. How long will it take for the drug's concentration to decrease to 25% of its original value?

Accepted Answer

16 hours

Answer

8 hours

Answer

24 hours

Answer

32 hours

Question 3

Comparing cisplatin and carboplatin, which factor primarily accounts for the difference in nephrotoxicity between these two chemotherapeutic agents?

Accepted Answer

Different rates of renal clearance

Answer

Variability in DNA adduct formation

Answer

Difference in protein binding

Answer

Dose-dependent cellular uptake

Question 4

What is the formula for calculating the therapeutic index (TI) of a drug?

Accepted Answer

LD50/ED50

Answer

EC50/IC50

Answer

IC50/EC50

Answer

ED50/LD50

Question 5

Which of the following statements is most accurate regarding why fentanyl is preferred over morphine for acute pain management in emergency settings?

Accepted Answer

Fentanyl is more suitable for acute pain management due to its rapid onset.

Answer

Morphine has a longer duration of action than fentanyl.

Answer

Fentanyl has lower lipid solubility than morphine.

Answer

Morphine is completely ineffective for acute pain management.

Question 6

Which route of administration provides the fastest onset of action for medications?

Accepted Answer

Intravenous

Answer

Oral

Answer

Intramuscular

Answer

Subcutaneous

Question 7

In a drug exhibiting first-order kinetics, how would an increase in dose affect the time required to reach the steady-state concentration?

Accepted Answer

It would not change

Answer

It would decrease

Answer

It would increase

Answer

It would double

Question 8

Which of the following drugs is not an inhibitor of P-glycoprotein?

Accepted Answer

Phenobarbitone

Answer

Verapamil

Answer

Quinidine

Answer

Erythromycin

Question 9

What is the primary reason for the short half-life of adenosine in the bloodstream?

Accepted Answer

Rapid uptake by red blood cells and endothelial cells

Answer

Uptake in subcutaneous tissue of adenosine

Answer

Renal excretion of adenosine

Answer

Spontaneous hydrolysis of adenosine

Question 10

Which of the following drugs has the highest nephrotoxic potential and requires the most careful monitoring in patients with renal failure?

Accepted Answer

Gentamicin

Answer

Ciprofloxacin

Answer

Vancomycin

Answer

Ampicillin

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?